Geron Company Description
Not far from the center of the controversy over human embryonic stem cell (hESC) research is Geron. The company hopes to parlay its work into viable therapies for various diseases and conditions. It is focused on lead anticancer drug candidate GRN163L, which inhibits telomerase, an enzyme that may prolong cellular life and prevents apoptosis (programmed cell death). The company is also continuing its work with hESCs to develop neural cells that could be implanted to treat spinal cord injury and other neurological disorders; heart muscle cells that could treat various cardiovascular conditions; and pancreatic islet cells that may restore insulin production in patients suffering from type I diabetes.
View the Comprehensive Company Description for Geron
The Company Description provides a historical perspective of Geron's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Geron's evolution in the marketplace.
